Cellectar Biosciences, Inc. CLRB

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001279704

None

No letter

3 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $15.0M
Warnings	late filer, thin data; fortress balance s... not computable: dilution, degenerate inputs, distress
Inputs computable	3 of 14
Graded from	filings received through Apr 30, 2026 193 days before the rescan; latest periodic filing 10-Q received Aug 13, 2026
Last close	$1.27 2026-11-06; market equity $12.0M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 4, 2026

We are a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid ether drug conjugate ? (PDC?) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. We believe that our PDC platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments, and we plan to develop PDCs both independently and through research and development collaborations.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 89.6						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Return on invested capital	not computable	9.3%				
required facts have no common fiscal period end						
Accruals ratio	6.6%	(6.6%)		89.6	802	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 73.3						
Twelve-month failure probability	not computable	0.08%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	(63.05)	(0.37)		90.6	747	2025-12-31
Net debt to EBITDA	not computable	1.82x				
EBITDA must exceed $100,000						
Interest coverage	not computable	(4.51x)				
one or more required annual facts are missing						
Current ratio	2.96x	2.94x		56.0	828	2025-12-31
Growth and financing						
Revenue growth, three-year compound	not computable	10.0%				
four annual observations are required; found 0						
Free cash flow growth, three-year compound	not computable	10.9%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	37.1%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Asset growth, three years	not computable	2.2%				
four consecutive annual observations are required						
Net share issuance, one year	not computable	2.5%				
prior share count is 64 days earlier						

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Late filer	found 1 NT 10-K/Q filings in the last eight quarters
Thin data	3 of 14 grade factors are computable; minimum is 7
Fortress balance sheet	cash minus debt is 3,582,569 USD; Altman Z is not used

What the price implies

at the 2026-11-06 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(45.7%)	(2.1%)	18
Distance from 52-week high	(69.1%)	(30.4%)	14
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(195.7%)	(1.0%)	4
Book value to price	2.53	0.29	96
Sales to price	not computable	0.30	
Composite equity issuance, five years	402.8%	20.8%	97
Relative strength against the sector, log excess return	(0.78)	(0.19)	18

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$34.0M
Operating cash flow, four quarters	-$19.5M
Months of runway	20.9
Days since last periodic filing	88 (10-Q received Aug 13, 2026)
Median daily dollar volume, 63 sessions	$117,535

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$21.8M	2025-12-31	2026-03-04	10-K	26-023167
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$23.1M	2025-12-31	2026-03-04	10-K	26-023167
3	assets	us-gaap:Assets	$15.0M	2025-12-31	2026-03-04	10-K	26-023167
4	assets	us-gaap:Assets	$25.5M	2024-12-31	2026-03-04	10-K	26-023167
5	current assets	us-gaap:AssetsCurrent	$14.0M	2025-12-31	2026-03-04	10-K	26-023167
6	current liabilities	us-gaap:LiabilitiesCurrent	$4.7M	2025-12-31	2026-03-04	10-K	26-023167
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$269.1M	2025-12-31	2026-03-04	10-K	26-023167
8	operating income	us-gaap:OperatingIncomeLoss	-$23.0M	2025-12-31	2026-03-04	10-K	26-023167
9	book equity	us-gaap:StockholdersEquity	$8.5M	2025-12-31	2026-03-04	10-K	26-023167
10	liabilities	us-gaap:Liabilities	$5.1M	2025-12-31	2026-03-04	10-K	26-023167
11	total debt	us-gaap:LongTermDebt	$330,222	2015-12-31	2016-10-20	10-K/A	16-128786
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$3.9M	2015-12-31	2018-03-21	10-K	18-016175
13	operating income	us-gaap:OperatingIncomeLoss	-$8.8M	2015-12-31	2017-03-15	10-K	17-014611
14	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$362,502	2015-12-31	2017-03-15	10-K	17-014611
15	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$5,880	2025-12-31	2026-03-04	10-K	26-023167
16	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$47.6M	2024-12-31	2026-03-04	10-K	26-023167
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$104,195	2024-12-31	2026-03-04	10-K	26-023167
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$32.4M	2023-12-31	2025-03-13	10-K	25-000329
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$864,038	2023-12-31	2025-03-13	10-K	25-000329
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$25.2M	2022-12-31	2024-10-29	10-K/A	24-001704
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$225,971	2022-12-31	2024-10-29	10-K/A	24-001704
22	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$291,653	2024-12-31	2026-03-04	10-K	26-023167
23	operating income	us-gaap:OperatingIncomeLoss	-$51.8M	2024-12-31	2026-03-04	10-K	26-023167
24	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$44.5M	2024-12-31	2026-03-04	10-K	26-023167
25	income tax	us-gaap:IncomeTaxExpenseBenefit	$66,000	2024-12-31	2026-03-04	10-K	26-023167
26	current assets	us-gaap:AssetsCurrent	$24.3M	2024-12-31	2026-03-04	10-K	26-023167
27	current liabilities	us-gaap:LiabilitiesCurrent	$9.4M	2024-12-31	2026-03-04	10-K	26-023167
28	current assets	us-gaap:AssetsCurrent	$10.5M	2023-12-31	2025-03-13	10-K	25-000329
29	current liabilities	us-gaap:LiabilitiesCurrent	$25.4M	2023-12-31	2025-03-13	10-K	25-000329
30	assets	us-gaap:Assets	$12.1M	2023-12-31	2025-03-13	10-K	25-000329
31	assets	us-gaap:Assets	$21.6M	2023-09-30	2024-10-29	10-K/A	24-001704
32	shares outstanding	dei:EntityCommonStockSharesOutstanding	4,240,129	2026-04-29	2026-04-30	10-K/A	26-053090
33	shares outstanding	dei:EntityCommonStockSharesOutstanding	4,240,129	2026-02-24	2026-03-04	10-K	26-023167

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.